Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorNational and Kapodistrian University of Athens
About this trial
Hip fracture is a common injury in older adults and is often associated with serious complications, longer hospital stays, and increased risk of death. One of the most important causes of poor outcomes after hip fracture surgery is infection, including severe infections such as sepsis. Early identification of patients at higher risk for complications could help improve treatment and survival.
This study aims to examine whether a blood test parameter called Monocyte Distribution Width (MDW), along with other commonly used inflammatory markers, can help predict complications and survival in elderly patients with hip fracture. MDW is measured as part of a routine complete blood count and has shown promise in the early detection of infection and systemic inflammation.
Approximately 100 patients aged 65 years or older who are admitted to the hospital with a low-energy hip fracture will be included in this study. Blood tests will be performed at hospital admission, after surgery, and at other time points as part of standard clinical care. These tests include routine blood counts and inflammatory markers such as C-reactive protein (CRP), procalcitonin (PCT), antithrombin III, and MDW. No additional invasive procedures are required beyond standard medical care.
Researchers will collect information about each patient's medical history, overall health status, and daily activity level before the fracture. Patients will be followed after surgery to assess complications, length of hospital stay, and survival at 1 month, 3 months, and 1 year.
The results of this study may help determine whether MDW can be used as a simple and reliable marker to identify patients at higher risk of complications or death after hip fracture. This could support earlier intervention, closer monitoring, and improved care for elderly patients with hip fractures in the future.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged ≥65 years
Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture)
Admission to General Hospital of Attica KAT
Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers
Disqualifiers
Age <65 years
High-energy trauma-related hip fractures
Pathological fractures
Trial population
The study population includes approximately 100 geriatric patients aged 65 years and older admitted with low-energy hip fractures and treated surgically at the 2nd Orthopaedic Department of the General Hospital of Attica KAT. Participants undergo routine perioperative evaluation, including demographic and clinical data collection and laboratory assessment of inflammatory biomarkers such as monocyte distribution width (MDW), C-reactive protein, procalcitonin, and antithrombin III. Patients are followed prospectively to evaluate postoperative morbidity and all-cause mortality at 1 month, 3 months, and 12 months following surgery.
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 1 trial groupGroup A: Geriatric Patients With Hip Fracture
Trial outcomes
Primary outcomes
1
All-cause mortality
Assessment of all-cause mortality in geriatric patients with low-energy hip fracture and its association with Monocyte Distribution Width (MDW) values measured at admission and during hospitalization.
Time frame
Up to 12 months postoperatively.Secondary outcomes
1
Postoperative morbidity
Assessment of postoperative morbidity, including infectious and non-infectious complications, and its association with Monocyte Distribution Width (MDW) and other inflammatory markers (C-reactive protein, procalcitonin, antithrombin III).
Time frame
From postoperative day 1 through study completion, an average of 1 year.2
Incidence of sepsis
Occurrence of sepsis during hospitalization or postoperative follow-up, evaluated in relation to MDW values and other inflammatory biomarkers.
Time frame
From postoperative day 1 through study completion, an average of 1 year.3
Change in Monocyte Distribution Width (MDW) over time
Evaluation of changes in MDW values from admission through the postoperative period and at discharge, and their association with clinical outcomes.
Time frame
From hospital admission through hospital discharge, up to 14 days postoperatively.4
Length of hospital stay
Duration of hospitalization measured in days and its association with MDW and inflammatory marker levels.
Time frame
From the date of hospital admission until hospital discharge, assessed up to 30 days.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov